Nanobiotix SA (NBTX) Stock Price, Financials & Summary

Price chart

Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16

Key dataOct 16, 2026

Open$22.19

From 52W high−61.32%

Volume77771.00

Market cap$1.08B

P/E (TTM)—

P/S (TTM)113.0x

Div yield—

Key dataOct 16, 2026

Open

$22.19

From 52W high

−61.32%

Volume

77771.00

Market cap

$1.08B

ValuationView details →

P/E (Fwd)

129.8x

EV/EBITDA

−29.3x

P/E (TTM)

—

RSI (14)

25.4

MomentumView details →

1D Return

−4.18%

YTD Return

−6.16%

SummaryUpdated Jun 1, 2026

Nanobiotix S.A. (NASDAQ:NBTX) is a clinical-stage biotechnology company founded in 2003 and headquartered in Paris, France. The company went public on NASDAQ in December 2020. Nanobiotix specializes in developing nanotechnology-based therapeutic solutions for cancer treatment, with its lead product candidate NBTXR3 currently in advanced clinical trials. The company has established significant partnerships, most notably a global licensing agreement with Johnson & Johnson worth potentially over $2.5 billion, marking a major validation of its nanotechnology platform approach to oncology.

Ask drillr about Nanobiotix SA →

ValuationView details →

P/E (Fwd)

129.8x

P/E (TTM)

—

EV/EBITDA

−29.3x

EV/Sales

112.5x

P/S (TTM)

113.0x

P/B (TTM)

−29.0x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−623.28%

EBITDA Margin

−384.16%

ROE (TTM)

159.82%

ROA (TTM)

−41.57%

Asset Turnover

0.09x

GrowthView details →

Revenue YoY

−15.78%

EPS YoY

−0.92%

FCF YoY

−24.46%

Revenue CAGR 3Y

+83.77%

EPS CAGR 3Y

+65.28%

EBITDA YoY

+22.26%

MomentumView details →

1D Return

−4.18%

YTD Return

−6.16%

1Y Return

−15.25%

RSI (14)

25.4

vs 50D SMA

−37.62%

vs 200D SMA

−35.31%

Capital & dividendView details →

Debt/Equity

−3.19x

Current Ratio

1.44x

Quick Ratio

1.44x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.80

EPS Surprise

−64.70%

Beats (12Q)

3/12

Next Q EPS Est

$0.06

Avg Surprise (4Q)

−83.25%

Rev Surprise

268.93%

Financials snapshotView financials →

Revenue (TTM)

18.71M

Net Income (TTM)

−104.97M

Op. CF (TTM)

−69.46M

Next earningsApr 27, 2027 →

Latest newsMore news →

Nanobiotix appointed Arnd Christ as chief financial officer and member of its executive board, effective October 1, 2026, succeeding Bart Van Rhijn.15d ago

Nanobiotix reported its operational progress and financial results for the first half of 2026.22d ago

Similar companies

JW (Cayman) Therapeutics Co. Ltd02126.HK Vor Biopharma Inc.VOR Bicara Therapeutics Inc. Common StockBCAX Cloudbreak Pharma Inc.02592.HK Verastem, Inc.VSTM Alpha Tau Medical Ltd.DRTS Find similar companies →

Latest newsMore news →

Nanobiotix appointed Arnd Christ as chief financial officer and member of its executive board, effective October 1, 2026, succeeding Bart Van Rhijn.15d ago Nanobiotix reported its operational progress and financial results for the first half of 2026.22d ago